Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
96M
-
Number of holders
-
234
-
Total 13F shares, excl. options
-
68.8M
-
Shares change
-
+128K
-
Total reported value, excl. options
-
$3.17B
-
Value change
-
+$15.1M
-
Put/Call ratio
-
1.2
-
Number of buys
-
127
-
Number of sells
-
-108
-
Price
-
$46.13
Significant Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q2 2023
280 filings reported holding RARE - Ultragenyx Pharmaceutical Inc. - COMMON STOCK as of Q2 2023.
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) has 234 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 68.8M shares
of 96M outstanding shares and own 71.72% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (7.02M shares), RTW INVESTMENTS, LP (5.41M shares), WELLINGTON MANAGEMENT GROUP LLP (5.18M shares), BlackRock Inc. (5.07M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.61M shares), Clearbridge Investments, LLC (2.76M shares), SANDS CAPITAL MANAGEMENT, LLC (2.67M shares), STATE STREET CORP (2.47M shares), ALKEON CAPITAL MANAGEMENT LLC (1.94M shares), and FEDERATED HERMES, INC. (1.78M shares).
This table shows the top 234 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.